| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 197.6 | 0.0 |
| Profit before tax | -409.8 | -305.2 |
| Net income | -407.5 | -305.2 |
| EPS (diluted, $ a share) | $-1.90 | $-1.61 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Operating margin | -188.9% |
|---|
10-Q filed with the SEC, NASDAQ: RVMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Revolution Medicines, Inc.: key numbers
- Share price
- $166.87Close, Nov 16
- Market cap
- $36.1B
- Shares outstanding
- 216.29MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Revolution Medicines, Inc.
All →Revolution Medicines CFO Jack Anders Sells $6.72M of Stock
Jack Anders, CFO, sold 35,750 shares of Revolution Medicines, Inc. at $181.04 to $192.84 a share (average $188.10) in 11 transactions, worth $6.72M in total on Nov 11, 2026. Shares held after the trade: 119,216 (-7.7%).
- Value
- $6.72M
- Shares
- 35,750
- Average price
- $188.10
- Role
- CFO
- Holding change
- -7.7%
- Trade date
- Nov 11, 2026
Revolution Medicines Financial Results
Revolution Medicines reported financial results for the third quarter of 2026, highlighted by the U.S. commercial launch of RASONQUE (daraxonrasib) for metastatic pancreatic cancer. The product generated $197.6 million in net revenue during its first five weeks on the market, with over 5,000 unique patients treated. The company also received a positive CHMP opinion for the drug in the European Union.
- Term
- Q3 2026
“The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union.”
Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines
Revolution Medicines Insider Anthony Mancini Sells $432K of Stock
Anthony Mancini sold 2,310 shares of Revolution Medicines, Inc. at $186.99 a share, worth $432K in total on Oct 26, 2026. Shares held after the trade: 39,765 (-5.5%).
- Value
- $432K
- Shares
- 2,310
- Price
- $186.99
- Holding change
- -5.5%
- Trade date
- Oct 26, 2026
Revolution Medicines $250M Debt Financing with Royalty Pharma Development Funding, LLC
Revolution Medicines drew down a $250 million Tranche A senior secured term loan from Royalty Pharma following the FDA approval of RASONQUE. The loan bears interest at a floating rate of three-month Term SOFR plus 5.75% and is due in full on October 8, 2032. The company also elected not to exercise an option to sell an additional $250 million royalty interest to Royalty Pharma.
- Value
- $250M
- Counterparty
- Royalty Pharma Development Funding, LLC
- Term
- through Oct 2032
Revolution Medicines Chief Development Officer Alan B. Sandler Sells $1.28M of Stock
Alan B. Sandler, Chief Development Officer, sold 6,309 shares of Revolution Medicines, Inc. at $200.82 to $204.72 a share (average $202.14) in 5 transactions, worth $1.28M in total on Sep 29, 2026. Shares held after the trade: 52,559 (-0.6%).
- Value
- $1.28M
- Shares
- 6,309
- Average price
- $202.14
- Role
- Chief Development Officer
- Holding change
- -0.6%
- Trade date
- Sep 29, 2026
Revolution Medicines Director Elizabeth M. Anderson Sells $1.96M of Stock
Elizabeth M. Anderson, Director, sold 10,143 shares of Revolution Medicines, Inc. at $191.85 to $195.15 a share (average $193.04) in 5 transactions, worth $1.96M in total on Sep 22, 2026. Shares held after the trade: 4,333 (-2.3%).
- Value
- $1.96M
- Shares
- 10,143
- Average price
- $193.04
- Role
- Director
- Holding change
- -2.3%
- Trade date
- Sep 22, 2026